Detalles de la búsqueda
1.
Mutational landscape of inflammatory breast cancer.
J Transl Med
; 22(1): 374, 2024 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-38637846
2.
Coffee and tea consumption, patient-reported, and clinical outcomes in a longitudinal study of patients with breast cancer.
Cancer
; 128(19): 3552-3563, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35913436
3.
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
Br J Cancer
; 127(5): 886-891, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35715631
4.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687411
5.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794206
6.
Differentiation of groups of patients with cognitive complaints at breast cancer diagnosis: Results from a sub-study of the French CANTO cohort.
Psychooncology
; 30(4): 463-470, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33052613
7.
Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Breast Cancer Res
; 22(1): 98, 2020 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32928264
8.
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.
Br J Cancer
; 122(6): 759-765, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32001832
9.
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat
; 173(2): 397-406, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30357526
10.
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
Chin J Cancer Res
; 31(4): 586-600, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31564802
11.
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Breast Cancer Res
; 20(1): 88, 2018 08 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30086764
12.
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
Br J Cancer
; 118(6): e14, 2018 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29462131
13.
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
Support Care Cancer
; 26(12): 4097-4103, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29855772
14.
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 17(5): 600-11, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27032301
15.
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Cancer
; 122(19): 3032-40, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27315583
16.
Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.
Br J Cancer
; 114(1): 44-52, 2016 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-26657653
17.
Tolerance of Concurrent Adjuvant Radiation Therapy and Pembrolizumab for Triple Negative Breast Cancer: Real Life Experience.
Adv Radiat Oncol
; 9(3): 101384, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38495034
18.
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis.
Oncogene
; 43(16): 1214-1222, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38413796
19.
Treatment Response, Tumor Infiltrating Lymphocytes and Clinical Outcomes in Inflammatory Breast Cancer-Treated with Neoadjuvant Systemic Therapy.
Cancer Res Commun
; 4(1): 186-199, 2024 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38147006
20.
miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness.
Int J Cancer
; 133(7): 1614-23, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23526361